In a recent article, Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, shared her thoughts.

The fifth of the series, focusing on clinical trial trends, has now been published and can be read here:

As Natalia stated, “nowadays lentiviral vectors are the vectors of choice in one third of all cell and gene therapy trials. In many of these trials lentiviral vectors are administered ex-vivo”. However, she adds that in the course of 2023, our company noticed significant developments in clinical trials involving lentiviral vectors. These included a rise in trials employing an allogenic approach, a broader range of cells being transduced with lentiviral vectors (including NK cells and TILs), and an increased utilization of various pseudotypes. We at VIVEbiotech expect these trends to continue.

Thank you very much to Scrip Citeline Commercial for this opportunity.